Femasys Inc. (FEMY) Reports Q4 Loss, Lags Revenue Estimates

Company Performance - Femasys Inc. reported a quarterly loss of $0.23 per share, which was better than the Zacks Consensus Estimate of a loss of $0.25, but worse than the loss of $0.19 per share from the previous year, indicating an earnings surprise of 8% [1] - The company posted revenues of $0.58 million for the quarter ended December 2024, missing the Zacks Consensus Estimate by 41.80%, compared to revenues of $0.21 million a year ago [2] - Over the last four quarters, Femasys has surpassed consensus EPS estimates two times and topped consensus revenue estimates just once [2] Stock Outlook - Femasys shares have increased by approximately 38.2% since the beginning of the year, contrasting with the S&P 500's decline of -2.9% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.23 on revenues of $1.9 million, and for the current fiscal year, it is -$0.59 on revenues of $11 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Femasys belongs, is currently ranked in the top 28% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Femasys's stock performance [5]